Close menu




May 19th, 2021 | 08:39 CEST

CureVac, The Place Holdings, TUI - New start with great potential!

  • Investments
Photo credits: pixabay.com

Finally! Due to the positive development of the vaccination program and the successful testing strategy, the incidence figures in Germany are gradually decreasing. Industries that suffered heavily from the pandemic, such as tourism and air travel, are breathing a sigh of relief. While Germans are still planning more domestic vacations during the Whitsun vacations, bookings abroad for the summer are rising disproportionately. Other countries are also increasingly focusing on domestic tourism, with considerable potential for the respective operators.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , SG1Q02920318 , DE000TUAG000

Table of contents:


    China far ahead

    While in Europe, the third wave has just been flattened out and slow steps are being taken to return to certain normality, in China, everyday life has long since returned. There is a travel boom in the Middle Kingdom, primarily within the country. According to China's Ministry of Culture and Tourism, 102 million citizens took domestic trips during the annual National Day holiday in April 2021, a figure equivalent to 94.5% of the number of trips taken during the holiday in 2019, the year before COVID-19. Tourism has become a significant contributor to China's domestic economy and is a cornerstone of the government's long-term goal of creating a consumption-driven economy.

    The emergence of an affluent middle class supports this plan. Due to the increasing economic power of consumers and the extreme inclination of the Chinese towards gaming, advertising, consumption and entertainment, the entertainment market is flourishing and new concepts are being developed. In contrast, much of China is still in a nascent phase in project and city development. Here, The Place Holdings, which is traded on the SGX in Singapore and Frankfurt, has created a perfect symbiosis of its three business segments to meet the needs of the emerging population.

    Three models in one

    The Place Holdings focuses on integrating traditional stores with omnichannel strategies and digital solutions such as "new-retail" solutions, last-mile logistics, immersive virtual reality technology, and smart connectivity for businesses to take advantage of new growth opportunities in the digital economy. The Group has built a business platform to integrate new value propositions within its 3 core businesses: real estate development and management, cultural tourism, and media-related businesses.

    To date, the debt-free Company, which has around EUR 46 million in cash, has three acquisitions in its portfolio. In the case of the Reality Centre, which was acquired in 2020 for EUR 93 million, the experienced management speculates on the claim to bonus property ratios of between 25% to 30% if a change of use occurs under the Central Business District (CBD) Incentive Scheme. The Place Holdings hold a 20% stake in MCC Land's mixed development project adjacent to the Tanah Merah MRT interchange.

    The third project, a plot of land that has only been held by a subsidiary since November, saw news of a significant revaluation last week. The size of the land is approximately 270,500.64 square meters. It is strategically located within Mount Yuntai Tourist Township, where hospitality properties, wellness resorts, integrated retail and commercial developments, and theme parks are planned and some are currently under development.

    Compared to the property's valuation of EUR 14.27 million as of September 30, 2020, the property was valued at EUR 61.29 million, up 329%, after the zoning change by one of China's leading valuation firms, which will add EUR 47.02 million to the balance sheet. Currently, the market capitalization of the Company is EUR 370.48 million. Suppose you are interested in the real estate market 2.0. in Singapore, you cannot avoid The Place Holdings. However, one should strictly limit due to the low tradability in Germany.

    When will the approval come?

    Due to the possible patent release, Panic selling gave investors a second chance with the Tübingen-based vaccine manufacturer CureVac. The share price fell from a high of EUR 110 to a low of below EUR 75. After forming a double bottom, however, the price recovered and closed the torn downward gap at around EUR 90. Yesterday, the share tested resistance at EUR 95. Breaking through the EUR 100 mark, at which the value has already failed three times on a sustained basis, is likely to be a more challenging task. Driven by the news, this could happen in June. Currently, CureVac is still in clinical trials; an application for approval should follow soon. The Tübingen-based Company is also well on schedule with its research into a second-generation vaccine that is supposed to be particularly effective against mutations. Clinical trials are expected to begin in the third quarter. If the first vaccine is approved in June, we expect a test of the old highs at EUR 125.40, at least in the short term.

    Hope dies last

    From summer, everything should get better. After further lockdowns and postponements, the travel group TUI hopes for a quick recovery of travel in the summer months. Slowly, it is also high time if one does not want to once again pump the already plundered state coffers.
    In the first two fiscal quarters of 2020/2021, from October to March, the world's largest travel provider accumulated a loss typical for the time of year. Still, at just under EUR 1.48 billion, this was more than 70% higher than in the same period last year. Currently, TUI has cash and cash equivalents of EUR 1.7 billion, with a cash outflow of EUR 300 million per month at last count. The state pumped a total of EUR 4.3 billion into the Hanover-based Group to prevent insolvency. Market capitalization is currently EUR 2.87 billion. Even though the travel business is picking up again, TUI faces major challenges in the future. Due to the uncertainties, we do not recommend an investment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read